refractory or recurrence primary immune thrombocytopenia
Conditions
Interventions
Case series:Sirolimus treats refractory or recurrence primary immune thrombocytopenia
Sponsors
Department of Hematology, Xiniao Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged between 18 to 80 years, male and female; 2. The clinical diagnosis is refractory or recurrence ITP patients which need treatment (platelet count < 30 x 10^9/L); 3. Understand the research program and voluntarily signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients participated in other clinical trials one month ago; 2. Patients have a poor clinical outcome whit sirolimus treatment; 3. Patients are using mabthera and splenectomy treatment; 4. HIV infection, hepatitisc antibody positive or hepatitisb surface antigen positive; 5. The following biochemical indexes: ALT/AST is greater than 1.5 times the normal limit, total bilirubin, blood lipid 1.2 times greater than normal; 6. Pregnancy or breastfeeding women; 7. Have uncontrolled systemic infection or combined with other serious diseases; 8. Researchers think that has any cause which the participants can't finish this study or bring obvious risk of subjects.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the effectiveness;safety; | — |
Countries
China
Contacts
Public ContactZhang Xi
Department of Hematology, Xiniao Hospital
Outcome results
None listed